Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ramsay Générale de Santé S.A. (GDS.PA)
Paris, IF, FR
Ramsay Générale de Santé S.A., headquartered in Paris, France, manages a network of hospitals across the nation. These facilities provide a wide spectrum of healthcare services, including specialized care in anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity management, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology. Furthermore, they conduct various surgical procedures such as thoracic, vascular, and endovascular interventions. Founded in 1987, the company adopted its current name in December 2015, having previously been known as Générale de Santé SA. Ramsay Générale de Santé S.A. functions as a subsidiary of Ramsay Health Care Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.98% | +7.98% | +16.40% | +4.55% | +28.35% | +23.92% | +6.48% | -43.07% | -40.87% | -10.32% | -38.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+4.7% Q4'25: +98.4% (vs Q2'24)
-
EPS growth Medical - Care Facilities: +19.2%+0.0% Q4'25: -10.3% (vs Q2'24)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+6.7% ★ Q4'25: -0.3% (vs Q2'24)
-
EBIT margin Medical - Care Facilities: +11.3%+3.2% Q4'25: +2.6% (vs Q2'24)
-
ROIC Medical - Care Facilities: +6.8%+3.4% Q4'25: +4.0% (vs Q2'24)
-
Share dilution Medical - Care Facilities: +0.0%+0.3% Q4'25: -4.9% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×6.81× Q4'25: 5.14× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2002 actual |
Jun 2003 actual |
Jun 2004 actual |
Jun 2005 actual |
Jun 2006 actual |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
988.01M
est.
|
1.15B
est.
|
1.25B
est: 1.15B (+8.6%)
|
1.44B
est: 1.27B (+13.2%)
|
1.74B
est: 1.45B (+19.8%)
|
1.91B
est: 1.76B (+8.0%)
|
1.98B
est: 1.93B (+2.8%)
|
2.05B
est: 2.02B (+1.2%)
|
1.93B
est: 2.06B (-6.7%)
|
1.96B
est: 2.03B (-3.8%)
|
1.93B
est: 2.01B (-3.8%)
|
1.87B
est: 2.00B (-6.6%)
|
1.71B
est: 1.90B (-10.1%)
|
1.72B
est.
|
2.23B
est: 1.73B (+28.9%)
|
2.23B
est: 1.75B (+27.5%)
|
| EBITDA |
133.30M
est.
|
82.27M
est.
|
150.00M
est: 73.31M (+104.6%)
|
174.40M
est: 85.49M (+104.0%)
|
403.10M
est: 109.65M (+267.6%)
|
212.80M
est: 147.28M (+44.5%)
|
275.80M
est: 377.75M (-27.0%)
|
249.10M
est: 165.50M (+50.5%)
|
203.00M
est: 127.79M (+58.8%)
|
157.80M
est: 132.22M (+19.3%)
|
244.40M
est: 121.70M (+100.8%)
|
271.40M
est: 74.09M (+266.3%)
|
191.10M
est: 174.81M (+9.3%)
|
227.68M
est.
|
269.80M
est: 121.23M (+122.6%)
|
267.70M
est: 236.38M (+13.2%)
|
| EBIT |
47.56M
est.
|
89.59M
est.
|
70.10M
est: 66.49M (+5.4%)
|
92.00M
est: 67.53M (+36.2%)
|
311.70M
est: 82.27M (+278.9%)
|
109.60M
est: 112.19M (-2.3%)
|
159.80M
est: 342.32M (-53.3%)
|
128.20M
est: 112.22M (+14.2%)
|
82.90M
est: 163.20M (-49.2%)
|
32.50M
est: 129.37M (-74.9%)
|
119.90M
est: 102.55M (+16.9%)
|
150.00M
est: 50.22M (+198.7%)
|
76.10M
est: 127.66M (-40.4%)
|
81.23M
est.
|
107.90M
est: 79.95M (+35.0%)
|
129.90M
est: 84.33M (+54.0%)
|
| Net Income |
44.83M
est.
|
24.17M
est.
|
27.40M
est: 15.14M (+80.9%)
|
40.90M
est: 18.07M (+126.4%)
|
225.40M
est: 31.39M (+618.0%)
|
45.60M
est: 49.66M (-8.2%)
|
87.20M
est: 246.44M (-64.6%)
|
42.40M
est: 47.92M (-11.5%)
|
37.90M
est: 88.72M (-57.3%)
|
-28.50M
est: 41.74M (-168.3%)
|
55.70M
est: 34.55M (+61.2%)
|
111.30M
est: -28.46M (+491.1%)
|
19.70M
est: 52.95M (-62.8%)
|
65.48M
est.
|
36.90M
est: 18.27M (+101.9%)
|
57.00M
|
| SGA |
37.46M
est.
|
654.68M
est.
|
—
est: 673.97M (-100.0%)
|
—
est: 734.91M (-100.0%)
|
—
est: 817.86M (-100.0%)
|
—
est: 959.18M (-100.0%)
|
—
est: 1.05B (-100.0%)
|
—
est: 1.11B (-100.0%)
|
83.10M
est: 1.14B (-92.7%)
|
—
est: 1.15B (-100.0%)
|
—
est: 1.09B (-100.0%)
|
156.80M
est: 1.10B (-85.8%)
|
141.10M
est: 1.06B (-86.7%)
|
63.99M
est.
|
473.30M
est: 882.19M (-46.3%)
|
488.60M
est: 66.43M (+635.5%)
|
| EPS |
0.41
est.
|
0.42
est.
|
0.65
est: 0.30 (+114.4%)
|
0.97
est: 0.67 (+45.4%)
|
4.20
est: 0.99 (+325.0%)
|
0.78
est: 1.04 (-25.0%)
|
1.48
est: 1.03 (+43.5%)
|
0.71
est: 0.86 (-17.0%)
|
0.58
est: 0.48 (+20.3%)
|
-0.47
est: 0.67 (-170.3%)
|
0.92
est: 0.50 (+83.5%)
|
1.83
est: 0.72 (+153.6%)
|
0.32
est: 0.56 (-43.1%)
|
0.59
est.
|
0.45
|
0.70
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pascal Roche | Chief Executive Officer | 1M | male |
| Clement Lafaix | Group Financial Director | — | male |
| Henrik Brehmer | Group Director of Strategy & Public Affairs | — | male |
| Isabelle Metref | Head of Investor Relations | — | female |
| Jerome Brice | Managing Director of France | — | male |
| Laurence Pinot-Lacan | Group Legal Director & Secretary of the Board of Director | — | female |
| Margareta Danelius | Chief Medical Officer | — | female |
| Maria Arnoux | Chief of Staff to Pascal Roché | — | — |
| Brigitte Cachon | Group Impact & Sustainability Director | — | female |
| Pierre Duperat | Director of Group Investments and Risks | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GDS.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
